CD33 and breast carcinoma: In the present work, we observed a significant positive correlation between CD33+ MDSCs and PD-1−PD-L1+ Bregs, and the level of MDSCs was an independent prognostic factor and might be a promising biomarker for evaluating breast cancer patient prognosis.